These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32543241)

  • 21. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
    Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
    Elkjaer ML; Lohse RM; Burton M; Mendoza JP; Thomassen M; Sejbaek T; Illes Z
    J Neuroimmunol; 2023 Aug; 381():578145. PubMed ID: 37393851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
    Yadav SK; Soin D; Ito K; Dhib-Jalbut S
    J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
    Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
    J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
    J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population.
    Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C
    Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
    Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
    Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.